Latest California Healthline Stories
The ‘scary’ findings show a discouraging lack of progress in cleaning the devices, despite more vigorous efforts in the wake of deadly superbug outbreaks, experts say.
California and federal officials have cracked down on a major compounding pharmacy they say posed a threat to public safety, but their actions are worsening shortages of medications that doctors rely on to keep their patients out of pain.
Suffering Americans seek medical marijuana as an alternative to opioids and other powerful pharmaceuticals. Though legal in 29 states, some doctors say the lack of strong data makes it hard to recommend. One researcher at the University of California-San Diego plans to use federally grown and controlled marijuana to study the effect of cannabidiol, a compound found in pot, on the neuropathic pain of HIV patients.
Kaiser Health News reporter Sarah Jane Tribble sat down with Food and Drug Administration Commissioner Scott Gottlieb on C-SPAN’s “Newsmakers” program. The conversation ranged from how the nation should combat the opioid epidemic to reining in drug prices.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Anna Edney of Bloomberg News and Margot Sanger-Katz of The New York Times discuss the apparent demise of bipartisan legislation aimed at shoring up parts of the Affordable Care Act. They also discuss aggressive new efforts by the Food and Drug Administration to regulate tobacco products. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.
In a historic move, the Food and Drug Administration stated its intent Thursday to require tobacco companies to cut nicotine levels in their products to make them less addictive. Stripping cigarettes of addictive power could lead an estimated 5 million adults to quit smoking within a year of the plan.
In an exclusive interview, FDA Commissioner Scott Gottlieb describes what he’s doing to spur competition and bring down drug prices.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Controversial research methods by university researcher unlikely to prompt federal response or institutional change, experts say.